Generic Injectables Market Overview
The generic injectables market is anticipated to reach USD 39.42 Billion by 2030 at 14.5% CAGR during the forecast period 2022-2030.
Lower centre around upgradation of the medical care framework and nature of the administrations in a couple of immature nations could present critical difficulties to the conventional injectable designers.
But, with undertakings zeroing in on attempting to be more ready for future necessities and guaranteeing a steadier stockpile chain will guarantee market's solid development in the following couple of years. Significant designers of conventional injectables are attempting to redirect their money in-stream generally on thorough exploration exercises, which centre around creating and commercializing inventive medication conveyance frameworks.
Blossoming old patient base, rising weight of different wellbeing problems, including heart, malignant growth, and diabetes, joined with the increased utilization of conventional injectables overall will be significant for the market in ensuing years.
Government bodies alongside the monetary specialists across various nations are setting new projects as well as monetary plans for the nonexclusive injectables market engineers. The monetary guides given to the endeavors to improve their business discernment will end up being extraordinary open doors later on.
Based on area, the nonexclusive injectables market is sectioned into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-portioned into North America and Latin America. The North American district is additionally sectioned into the US and Canada. The European area is isolated into two, specifically, Western Europe and Eastern Europe.
Western Europe is additionally grouped into Germany, Italy, France, the UK, Spain, and the remainder of Western Europe. The Asia-Pacific locale is sub-fragmented into Japan, China, India, Australia, South Korea, and the remainder of Asia-Pacific. The nonexclusive injectables market in the Middle East and Africa has been fragmented into the Middle East and Africa.
Generic Injectables Market Segmentation
The generic injectables market is segmented on the basis of product type, container, application, distribution channel, and end user.
The market, by product type is categorised into monoclonal antibodies, cytokines, insulin, vaccines, and others.
On the basis of container, the market is segmented into vials, ampoules, premix, and prefilled syringes.
Based on application, the market of generic injectables is segmented oncology, anaesthesia, anti-infectives, parenteral nutrition, cardiovascular, and others.
The market, by distribution channel is categorised into hospital pharmacy, retail pharmacy, drug stores, and online prescription stores.
On the basis of region, the generic injectables market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The market of generic injectables in the Middle East and Africa has been segmented into the Middle East and Africa.
Generic injectables Market Regional Insights
Global Generic injectables Market Share (%), by Region
Sources: Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, National Institutes of Health
It is projected that the Americas dominated the generic injectables market owing to the growth of the market in the North American region. This is largely attributed to the factors such as an increase in drug shortages, especially in the US, along with patent expiry of a number of blockbuster drugs. Even though the generic injectable industry has operations across the globe, majority of largest manufacturers produce a large volume of generic injectable in the U.S. Moreover, in the U.S. over 70% of hospital patients receive generic injectable drugs, which is further pushing the demand for generic injectable in North America.
Europe is currently holding a considerable amount of market share in the generic injectables market owing to the advantages offered by generic injectables, governments in various countries are supporting their manufacture. For instance, in June 2017, Baxter signed an agreement with Dorizoe for life sciences company manufacturing generic sterile injectable. This alliance is anticipated to develop more than 20 generic injectable products including cardiovascular and oncolytic medicines.
Asia-Pacific was projected to be the fastest growing region for the market of generic injectables. This owes to the infrastructural development and increase in outsourcing of research activities to the contract research organizations (CROs) at relatively low cost in this region. For example, the Sun Pharma’s acquisition of Pharmalucence in 2014 that resulted in benchmarking sales of generic sterile injectable.
The Middle East and Africa holds the least share in the generic injectables market due to the presence of economically diverse countries, and less initiatives taken by the government.
Teva Pharmaceutical Industries Ltd. announces that it has received FDA approval for its new generic version of Trulicity (dulaglutide), a GLP-1 receptor agonist for the treatment of type 2 diabetes. Trulicity is a long-acting injectable medication that is administered once a week.
Mylan N.V. announces that it has launched a new generic version of Humira (adalimumab), a TNF inhibitor for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Humira is a biologic drug that is administered as an injection every two weeks.
Sandoz AG announces that it has launched a new generic version of Neulasta (pegfilgrastim), a G-CSF for the treatment of neutropenia. Neulasta is a biosimilar drug that is administered as an injection once a day.
Several companies announce new partnerships to develop and commercialize new generic injectables. These partnerships aim to develop new therapies for a variety of diseases, including cancer, autoimmune diseases, and infectious diseases.
A new study published in the journal Clinical Pharmacology and Therapeutics finds that a new type of generic injectable is effective in treating patients with advanced melanoma. The study found that the new generic injectable was as effective as the brand-name drug and had a lower side effect profile.
Another study published in the journal Cancer found that a new type of generic injectable can be used to treat patients with type 1 diabetes. The study found that the new generic injectable was effective in producing insulin in the body and reversing the symptoms of diabetes.
Cosette Pharmaceuticals Inc., a drug firm has sent off Prochlorperazine Edisylate infusion, which is the nonexclusive identical to the Compazine Injection 10mg/2ml. Prochlorperazine Edisylate helps control serious queasiness as well as retching. Prochlorperazine Edisylate likewise helps treating schizophrenia.
Generic Injectables Product type Outlook
- Monoclonal antibodies
Generic Injectables Container Outlook
- Prefilled syringes
Generic Injectables Application Outlook
- Parenteral nutrition
Generic Injectables Distribution Channel Outlook
- Hospital pharmacy
- Retail pharmacy
- Drug stores
- Online prescription stores
Generic Injectables Region Outlook
- North America
- Latin America
- Western Europe
- Rest of Western Europe
- Eastern Europe
- South Korea
- Rest of Asia-Pacific
- The Middle East & Africa
Market of Generic Injectables, Key Players
- Novartis AG (Sandoz International GmbH)
- Fresenius SE & Co. KGaA
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals plc
- Reddy’s Laboratories
- Aurobindo Pharma
- Zydus Cadila
- GlaxoSmithKline plc
- AstraZeneca plc.
- Pharmaceutical & Biopharmaceutical companies
- Biotechnological companies
- Government institutions
- Research and Development (R&D) companies
- Medical research laboratories
| Market Size in 2030
| USD 39.42 Million
| 14.5% (2022-2030)
| Base Year
| Forecast Period
| Historical Data
| Forecast Units
| Value (USD Billion)
| Report Coverage
| Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
| Segments Covered
| Product Type, Container, Application and Distribution Channel
| Geographies Covered
| North America, Europe, Asia-Pacific, and Rest of the World (RoW)
| Key Vendors
| Novartis AG (Sandoz International GmbH), Baxter, Fresenius SE & Co. KGaA, Mylan N.V., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals plc, Sanofi, Biocon, Reddy’s Laboratories, Aurobindo Pharma, Zydus Cadila, GlaxoSmithKline plc, AstraZeneca plc.
| Key Market Opportunities
| joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments
| Key Market Drivers
| Increasing prevalence of chronic and infectious disease along with the advancement in research and academic initiatives
Generic Injectables Market Highlights:
Frequently Asked Questions (FAQ) :
The global generic injectables market is expected to exhibit a strong 14.5% CAGR over the forecast period from 2022 to 2030.
The increasing prevalence of chronic and infectious diseases is driving the demand for effective generic injectables.
Key types of generic injectables include monoclonal antibodies, cytokines, insulin, vaccines, and others.
The Americas is likely to dominate the global generic injectables market.
Leading players in the generic injectables market include Novartis, Baxter, Sanofi, Biocon, and Zydus Cadila, among others.
Key Questions Answered
Request Free Sample
- ✅Global Market Outlook
- ✅In-depth analysis of global and regional trends
- ✅Analyze and identify the major players in the market, their market share, key developments, etc.
- ✅To understand the capability of the major players based on products offered, financials, and strategies.
- ✅Identify disrupting products, companies, and trends.
- ✅To identify opportunities in the market.
- ✅Analyze the key challenges in the market.
- ✅Analyze the regional penetration of players, products, and services in the market.
- ✅Comparison of major players’ financial performance.
- ✅Evaluate strategies adopted by major players.
Why Choose Market Research Future?
Speak to Analyst
- ✅Vigorous research methodologies for specific market.
- ✅Knowledge partners across the globe
- ✅Large network of partner consultants.
- ✅Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- ✅Trusted by fortune 500 companies/startups/universities/organizations
- ✅Large database of 5000+ markets reports.
- ✅Effective and prompt pre- and post-sales support.